赵, 丰 – page 4 – eisai china lnc.-爱游戏app官网入口

tokyo and cambridge, mass., february 28, 2023 – eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and biogen inc. (nasdaq: biib, corporate headquarters: cambridge, massachusetts, ceo: christopher a. viehbacher, “biogen”) announced today that the biologics license application (bla) for lecanemab (brand name in the u.s.: leqembi™), an investigational anti-amyloid beta (aβ) protofibril antibody, has been designated for priority review by the national medical products administration (nmpa) in china. the priority review and approval procedure was implemented by the nmpa with the aim of accelerating research, development and launch of new medicines that have significant clinical value. under this procedure, the assessment period is expected to be shortened.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has been listed in the 2023 global 100 most sustainable corporations in the world (global 100), a global ranking by canada-based media and investment advisory company, corporate knights, inc. this marks eisai’s seventh inclusion on the list. ranked 53rd, eisai was the highest ranking company among global pharmaceutical companies (please visit here for the global 100 ranking).

tokyo and cambridge, eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and biogen inc. (nasdaq: biib, corporate headquarters: cambridge, massachusetts, ceo: christopher a. viehbacher, “biogen”) announced today that eisai has initiated submission of data for biologics license application (bla) to the national medical products administration (nmpa) of china for lecanemab (development code: ban2401), an investigational anti-amyloid beta (aβ) protofibril antibody.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has entered into an agreement to transfer the united states (u.s.) commercial rights for the anti-epileptic drug (aed) fycompa® (generic name: perampanel) ciii to catalyst pharmaceuticals, inc. (headquarters: the united states, “catalyst pharmaceuticals”), as well as to provide catalyst pharmaceuticals with an exclusive negotiation period for an asset in eisai’s epilepsy pipeline. eisai will maintain its rights to fycompa in countries and regions outside the u.s. and continue to contribute to patients with epilepsy. closing of the transaction is contingent on completion of review under antitrust laws in the u.s.